Page 418 - TBE_Book_V2_2019

Chapter 12b: TBE in Sweden

Table 2: TBE reporting and vaccine prevention in Sweden
Each diagnostic laboratory plus the responsible physician report to the
Public Health Agency of Sweden

Case definition:
TBEV-infection (viral TBE)
Suspected case:
- Epidemiological link
- Clinical symptoms consistent with TBE
- Pleocytosis (CSF) and/or neurological symptoms of encephalitis
- Detection of TBEV-specific serum IgM

Confirmed case:
Mandatory TBE At least one of the following:
reporting - Detection of TBE-specific IgM and IgG in serum
- Detection of TBE-specific IgM in CSF
- Seroconversion or significant titer rise in paired serum samples
- Detection of TBEV RNA in CSF (or post-mortem in brain tissue)
- Detection of TBEV RNA in serum

Note: Previous TBE vaccination and/or immunosuppression influence
the patients’ antibody responses and thus repeated sampling may be
necessary for an accurate diagnosis. Also earlier infections, or
vaccinations, against other flaviviruses may complicate the diagnostics
due to cross-reactive antibodies.

Source: The Public Health Agency of Sweden (see below)
Other TBE
No
surveillance
36–40% with sequelae (after 1 year);
Clinical characteristics 7-8
Mortality: 1.4%
Available FSME-immun (Pfizer) introduced in 1988 and Encepur (Novartis Vaccines)
vaccines introduced in 2003. 500,000–600,000 doses/year 13,16

Vaccination Revised each year
recommendations and
No reimbursement
reimbursement

Vaccine uptake by
age group/risk group/ No data available
general population

The Public Health Agency of Sweden
Name, address/website SE-171 82 Solna , Sweden
of TBE NRC
www.folkhalsomyndigheten.se

413